Journal of Thoracic Oncology · 2017 · 271 citations · 64 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyMolecular OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsTumor-infiltrating LymphocytesCd4+ Tumor-infiltrating LymphocytesCd8+ Tumor-infiltrating LymphocytesImmune Checkpoint Ligand ExpressionKaplan-meier Confidence IntervalsKaplan-meier Survival EstimatesPd-l1 BlockadeProtein Expression Biomarkers
64
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text